Flexible initial dosing of atorvastatin based upon initial low-density lipoprotein cholesterol levels in type 2 diabetic patients

Korean Journal of Internal Medicine

Volumn 23, Issue 1, 2008, Pages 22-29

  Son, Ho Young ^a   Yoon, K H ^a   Choi, Y H ^a   Kwon, H S ^a   Ko, S H ^a   Lee, I K ^b   Kim, H S ^b   Park, K K ^b   Kim, M J ^b   Woo, J T ^c   Kim, Y S ^c   Choi, D S ^d   Lee, M K ^e   Kim, H J ^e   Park, K S ^f   Lee, H K ^f   Park, J Y ^g   Koh, E H ^g   Lee, H C ^h   Cha, B S ^h   Chung, M Y ⁱ   Cho, D H ⁱ   Kim, Y K ^j,k   Kim, I J ^j   Ku, B J ^k   more..

^a The Catholic University of Korea   (South Korea)

^b Keimyung University   (South Korea)

^c Kyung Hee University Hospital   (South Korea)

^d Korea University College of Medicine   (South Korea)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Chonnam National University Medical School   (South Korea)

^j Pusan National University School of Medicine   (South Korea)

^k Chungnam National University College of Medicine   (South Korea)

more..

Author keywords

Atorvastatin; Flow mediated endothelium dependent dilatation (FMD); Flow mediated endothelium independent dilation (EID); Low density lipoprotein cholesterol (LDL C); Type 2 diabetes mellitus

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DISEASE ASSOCIATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOTHELIAL DYSFUNCTION; FEMALE; HEADACHE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 72049123995     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2008.23.1.22     Document Type: Article

References (22)

1. Eisenberg DA. Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials. Am J Med 104:2S-5S, 1998
2. Kannel WB. Range of serum cholesterol values in the population developing coronary artery disease. Am J Cardiol 76:69C-77C, 1995
3. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E. Cardiovascular events and their reduction with pravastatin in diabetic and glucose intolerant myocardial infarction survivors with average cholesterol levels. Circulation 98:2513-2519, 1998
4. Collins R, Armitage J, Parish S, Seligh P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo controlled trial. Lancet 361:2005-2016, 2003
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393, 2003
6. Wiklund O, Haversen L, Pettersson C, Hulten LM. How can we prevent cardiovascular disease in diabetes. J Intern Med 262:199-207, 2007
7. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult treatment panel III). JAMA 285:2486-2497, 2001
8. Haffner SM. Dyslipidemia management in adults with dabetes. Diabetes Care 27(Suppl 1):S68-S71, 2004
9. Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G, Pauciullo P, Sirtori C, Egros F, Fayyad R, Nawrocki JW. Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 130:191-197, 1997
10. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. Am J Cardiol 87:554-549, 2001
11. Heinonen TM, Stein E, Weiss SR, McKenney JM, Davidson M, Shurzinske L, Black DM. The lipid-lowering effects of atorvastatin, a new HMG-CoA reductase inhibitor: results of a randomized, double masked study. Clin Ther 18:853-863, 1996
12. Fonseca V, Desouza C, Asnani S, Jialal I. Nontraditional risk factors for cardiovascular disease in diabetes. Endocr Rev 25:153-175, 2004
13. Marchesi S, Lupattelli G, Siepi D, Schillaci G, Vaudo G, Roscini AR, Sinzinger H, Mannarino E. Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women. J Cardiovasc Pharmacol 36:617-621, 2000
14. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Diabetes Metab 27:436-447, 2001
15. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22, 2002
16. Jones PH, Hunninghake DB, Ferdinand KC, Stein EA, Gold A, Caplan RJ, Blasetto JW. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non high density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia. Clin Ther 26:1388-1399, 2004
17. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81:582-587, 1998
18. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315:1046-1051, 1986
19. Gough SC, Grant PJ. The fibrinolytic system in diabetes mellitus. Diabet Med 8:898-905, 1991
20. Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 47:648-657, 2000
21. Hernandez Perera O, Perez Sala D, Navarro Antolin J, Sanchez Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 101:2711-2719, 1998
22. van den Akker JM, Bredie SJ, Diepenveen SH, van Tits LJ, Stalenhoef AF, van Leusen R. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C reactive protein and in vivo oxidized LDL. J Nephrol 16:238-244, 2003